Caladrius Biosciences (CLBS) received a Buy rating and a $18.50 price target from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed yesterday at $4.52.
Pantginis said:
“Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We are assuming coverage at $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -16.9% and a 27.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.65 and a one-year low of $3.04. Currently, Caladrius Biosciences has an average volume of 40.17K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
